Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01241448 · ClinicalTrials.gov registry record · Phase 2
A Study of LY2409021 in Patients With Type 2 Diabetes
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 263
- Enrollment target
NCT01241448 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 263 participants.
The verdict
NCT01241448, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 263 participants
- Enrollment target
Study Summary
LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is designed to compare LY2409021 given alone or given in combination with metformin against placebo the change in hemoglobin A1c after a 24-week treatment period.
Interventions
- DRUG Placebo
- DRUG LY2409021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01241448
The ClinicalTrials.gov registry entry for NCT01241448 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 263 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01241448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01241448 about?
NCT01241448 is a clinical study titled "A Study of LY2409021 in Patients With Type 2 Diabetes". LY2409021 is being evaluated for possible treatment in type 2 diabetes. This study is designed to compare LY2409021 given alone or given in combination with metformin against placebo the change in hemoglobin A1c after a 24-week treatment period.
What is the current status of trial NCT01241448?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 263 participants. The study started on 2011-01. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01241448?
The interventions under investigation include: Placebo (DRUG), LY2409021 (DRUG).
Who is sponsoring clinical trial NCT01241448?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.